Serious Event

Serious Event

Serious Adverse Events (SAEs) are adverse events that result in death, are life-threatening, require or prolong hospitalization, cause persistent or significant disability/incapacity, or are congenital anomalies/birth defects. Each serious event is categorized by term, organ system, assessment type, and source vocabulary to provide standardized reporting across clinical trials.

Serious Event path is as follows:

Study -> Results Section -> Adverse Events Module -> Serious Event

Study -> Results Section -> Adverse Events Module -> Serious Event -> Serious Event Stats

Serious Event


Ignite Creation Date: 2025-12-24 @ 10:43 PM
Ignite Modification Date: 2025-12-25 @ 8:14 PM
NCT ID: NCT03850535
Term: Myelodysplastic syndrome
Organ System: Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Assessment Type: NON_SYSTEMATIC_ASSESSMENT
Source Vocabulary: MedDra 23.0
Notes: None
Study: NCT03850535
Study Brief: A Study Evaluating the Safety and Efficacy of Idasanutlin in Combination With Cytarabine and Daunorubicin in Patients Newly Diagnosed With Acute Myeloid Leukemia (AML) and the Safety and Efficacy of Idasanutlin in the Maintenance of First AML Complete Remission
Serious Event Stats (If Any):

Serious Event Stats

Group ID # Events # Affected # At Risk View
EG000 0 0 4 View
EG001 0 0 9 View
EG002 0 0 6 View
EG003 1 1 4 View